Home » Stocks » ONTX

Onconova Therapeutics, Inc. (ONTX)

Stock Price: $0.266 USD 0.007 (2.74%)
Updated November 25, 4:00 PM EST - Market closed
After-hours: $0.268 +0.002 (0.75%) Nov 25, 7:51 PM

Stock Price Chart

Key Info

Market Cap 49.20M
Revenue (ttm) 204,000
Net Income (ttm) -24.48M
Shares Out 184.95M
EPS (ttm) -0.18
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a

Stock Quote

Trading Day November 25
Last Price $0.266
Previous Close $0.259
Change ($) 0.007
Change (%) 2.74%
Day's Open 0.256
Day's Range 0.255 - 0.269
Day's Volume 5,823,953
52-Week Range 0.103 - 1.560

More Stats

Market Cap 49.20M
Enterprise Value 25.00M
Earnings Date (est) Mar 29, 2021
Ex-Dividend Date n/a
Shares Outstanding 184.95M
Float 183.94M
EPS (basic) 1.04
EPS (diluted) -0.18
FCF / Share -0.13
Dividend n/a
Dividend Yield n/a
Earnings Yield n/a
FCF Yield n/a
Payout Ratio n/a
Shares Short 11.73M
Short Ratio 1.49
Short % of Float 6.38%
Beta 1.99
PE Ratio n/a
Forward PE n/a
P/FCF Ratio n/a
PS Ratio 241.16
PB Ratio 3.11
Revenue 204,000
Operating Income -24.47M
Net Income -24.48M
Free Cash Flow -22.98M
Net Cash 24.20M
Net Cash / Share 0.13
Gross Margin 1,070.10%
Operating Margin -11,993.14%
Profit Margin -11,997.50%
FCF Margin -11,265.20%
ROA -97.41%
ROE -792.84%
ROIC 334.20%
Stats based on trailing-twelve-month (ttm) numbers.

Analyst Forecasts

Analyst Ratings (4)

Buy 0
Overweight 0
Hold 4
Underweight 0
Sell 0

Analyst Consensus: Hold

Price Target

$0.30*
Low
0.30
Current: $0.266
High
0.30
Target: 0.30
*Average 12-month price target from 1 stock analysts.

Financial Performance

Financial numbers in millions USD.

Financial Overview

Year201920182017201620152014201320122011
Revenue2.181.230.795.5511.460.804.7546.191.49
Revenue Growth77.77%56.04%-85.81%-51.59%1332%-83.17%-89.71%3006.25%-
Gross Profit2.181.230.795.5511.460.804.7546.191.49
Operating Income-21.70-23.28-25.74-23.70-23.97-63.74-62.22-22.28-27.57
Net Income-21.50-20.57-24.09-19.67-23.98-63.68-62.54-29.91-26.29
Shares Outstanding14.384.120.600.300.150.140.070.010.01
Earnings Per Share-1.49-4.99-40.15-66.60-158.09-440.98-917.95-2,302.39-2,126.89
Operating Cash Flow-20.83-22.70-23.82-15.81-31.24-57.65-61.381.63-14.17
Capital Expenditures-0.06-----0.23-0.61-0.28-0.26
Free Cash Flow-20.89-22.70-23.82-15.81-31.24-57.88-61.991.35-14.43
Cash & Equivalents22.7316.974.0221.4519.8543.7110081.652.84
Total Debt--------0.62
Net Cash / Debt22.7316.974.0221.4519.8543.7110081.652.22
Assets23.6717.924.9823.2323.4547.3410583.854.46
Liabilities12.1012.5415.8418.1112.6123.7224.2540.8422.88
Book Value11.575.39-11.694.3010.0122.7580.41-158-138
Numbers in millions USD, except per-share numbers.

Company Profile

Company Details

Full Name Onconova Therapeutics, Inc.
Country United States
Employees 17
CEO Steven M. Fruchtman

Stock Information

Ticker Symbol ONTX
Stock Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Unique Identifier NASDAQ: ONTX
IPO Date July 25, 2013

Description

Onconova Therapeutics, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule product candidates to treat cancer. Its product candidates include Rigosertib IV, which is in Phase III clinical trial for patients with higher risk myelodysplastic syndromes (MDS); Rigosertib oral in combination with azacitidine that is in Phase II clinical trial for patients with higher-risk MDS; and Rigosertib oral, which is in Phase II clinical trial for patients with lower risk MDS. The company also develops Briciclib, which is in Phase I multi-site dose-escalation trial for patients with advanced solid tumors; and Recilisib that has completed four Phase I clinical trials for patients with acute radiation syndromes. The company has a license agreement with SymBio Pharmaceuticals Limited; a license, development, and commercialization agreement with Pint International SA; and a license and collaboration agreement with HanX Biopharmaceuticals, Inc. for the development, registration, and commercialization of ON 123300 in Greater China. Onconova Therapeutics, Inc. was founded in 1998 and is headquartered in Newtown, Pennsylvania.